Cart
sales@molnova.com
Solanezumab
CAS No. 955085-14-0
Solanezumab( —— )
Catalog No. M36734 CAS No. 955085-14-0
Solanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 613 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1454 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2595 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSolanezumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSolanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.
-
DescriptionSolanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetBeta Amyloid
-
RecptorBeta Amyloid
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number955085-14-0
-
Formula Weight144.1 (kDa)
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Honig LS, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018 Jan 25;378(4):321-330.?
molnova catalog
related products
-
Amyloid β Peptide (4...
Amyloid β-Peptide (1-42) human is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
-
Lecanemab
Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.
-
GRGDSPK acetate
GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.
